References

MMRV vaccine decision aid

  1. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2012;15.
  2. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Canberra: Australian Government Department of Health; 2019. Available from: immunisationhandbook.health.gov.au.
  3. Eldred BE, Dean AJ, McGuire TM, Nash AL. Vaccine components and constituents: responding to consumer concerns. Med J Aust 2006;184:170-5.
  4. Hutchins SS, Bellini WJ, Coronado V, et al. Population immunity to measles in the United States, 1999. J Infect Dis 2004;1:377713.
  5. Kutty PK, Kruszon-Moran DM, Dayan GH, et al. Seroprevalence of antibody to mumps virus in the US population, 1999-2004. J Infect Dis 2010;202:667-74.
  6. Hyde TB, Kruszon-Moran D, McQuillan GM, et al. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis 2006;1:505947.
  7. Prymula R, Bergsaker MR, Esposito S, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet 2014;383:1313-24.
  8. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004;1:377712.
  9. Offit PA, Quarles J, Gerber MA, et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 2002;109:124-9.
  10. Sorup S, Benn CS, Poulsen A, et al. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. Jama 2014;311:826-35.
  11. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41.
  12. Blyth CC, Macartney KK, McRae J, et al. Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration. Clin Infect Dis 2019;68:940-8.
  13. Hviid A, Hansen JV, Frisch M, Melbye M. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Ann Intern Med 2019;5:M18-2101.
  14. Omer SB, Yildirim I. Further Evidence of MMR Vaccine Safety: Scientific and Communications Considerations. Ann Intern Med 2019;5:M19-0596.
  15. Hull B, Hendry A, Dey A, et al. Immunisation coverage annual report, 2015. Commun Dis Intell 2018;15:43.
  16. Dabbagh A, Laws RL, Steulet C, et al. Progress Toward Regional Measles Elimination - Worldwide, 2000-2017. MMWR Morb Mortal Wkly Rep 2018;67:1323-9.
  17. Public Health England. Seasonal influenza vaccine uptake in children of primary school age: winter season 2017 to 2018. 2018. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/710482/Seasonal_influenza_vaccine_uptake_in_children_of_primary_school_age_winter_season_2017_to_2018.pdf (Accessed 11 September 2019).
  18. Plotkin S, Orenstein W, Offit P, Edwards K. Plotkin's Vaccines. 7th. Philadelphia: Elsevier; 2018.
  19. Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010;156:623-8.
  20. Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005;192:1686-93.

  • 1216 views